grossman lab banner

Doug Grossman

Doug Grossman

Doug Grossman, MD, PhD

Cancer Center Bio

Selected Achievements

Member, American Society for Clinical Investigation (2009)

US News & World Report's Top Doctors in Dermatology (2011, 2012)

Doug was born in Dallas, Texas, and headed east to Duke University in Durham, North Carolina where he majored in chemistry.  After college, feeling his roots, he returned to Texas.  Interested in a career as a physician scientist, he enrolled in the NIH Medical Scientist Training Program at the Baylor College of Medicine.  For his scientific training, he completed his PhD in 1992 in Immunology in the laboratory of Robert Rich, and then he completed his medical training and received his MD in 1994.  For his specialty training in dermatology, Doug went to Yale University in New Haven, Connecticut where he completed his internship and then a dermatology residency in 1998.  He remained at Yale for a research fellowship in cancer biology, where he worked with Dario Altieri, a luminary in the field of apoptosis research.  Following his work at Yale, he was recruited to the Huntsman Cancer Institute 2001, where he joined the University of Utah School of Medicine faculty in the Department of Dermatology.

Grossman's lab now studies the regulatory mechanisms of apoptosis, or programmed cell death, in melanocytes and keratinocytes, and dysregulation of apoptosis in both melanoma and non-melanoma skin cancer. In addition, they study nevus (atypical mole) senescence and the role of ultra-violet (UV) light-induced oxidative stress/damage in the development of melanoma. In collaborative studies with other investigators at Huntsman Cancer Institute, they are developing novel antioxidants to be used as chemopreventive agents in patients at risk for melanoma.  Doug is the principal investigator of a Phase II clinical trial that is currently running to test the protection afforded by the drug N-acetylcysteine against the harmful effects of UV skin exposure.

As a physician, Doug is now an expert in the early diagnosis and treatment of skin cancers.  He sees patients at risk for melanoma and non-melanoma skin cancer, with a special interest in patients who have a personal or family history of skin cancer or excessive sun exposure, and those at increased risk for melanoma who may have numerous or atypical moles or family members with melanoma.  To provide continuous care to his patients, he directs the Mole Mapping Project at the Huntsman Cancer Institute.  This involves total-body photography to allow monitoring of existing moles, and to enable detection of new moles over time, which is how melanomas usually develop.